Citius’ Leonard Mazur talks targeted immune therapy for CTCL

Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune system. And Citius Oncology is focused on developing and commercialising a targeted immune therapy for the initial indication of the treatment of persistent or recurrent CTCL. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals about the launch of its first FDA-approved drug, Lymphir, for CTCL. Mazur discusses the landscape of unmet need in this space, as well as Citius’ advancement of clinical trials in other areas without approved treatments and the future horizon for such oncological innovations. You can listen to episode 265 of the pharmaphorum podcast (https://pharmaphorum.com/podcasts)  in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts (https://podcasts.apple.com/gb/podcast...) , Spotify (https://open.spotify.com/show/1wbZ50I...) , Overcast, Pocket Casts, Podbean (https://pharmaphorum.podbean.com/) , and pretty much wherever else you download your other podcasts from.